S
Sandra Ortiz-Cuaran
Researcher at Claude Bernard University Lyon 1
Publications - 39
Citations - 1929
Sandra Ortiz-Cuaran is an academic researcher from Claude Bernard University Lyon 1. The author has contributed to research in topics: Medicine & Cancer. The author has an hindex of 17, co-authored 28 publications receiving 1466 citations. Previous affiliations of Sandra Ortiz-Cuaran include University of Cologne & International Agency for Research on Cancer.
Papers
More filters
Journal ArticleDOI
New insights into the role of EMT in tumor immune escape
Stéphane Terry,Pierre Savagner,Sandra Ortiz-Cuaran,Linda Mahjoubi,Pierre Saintigny,Jean Paul Thiery,Jean Paul Thiery,Jean Paul Thiery,Salem Chouaib +8 more
TL;DR: Current knowledge of how cellular heterogeneity and plasticity could be involved in shaping the tumor microenvironment (TME) and in controlling antitumor immunity is reviewed.
Journal ArticleDOI
Rationale for co-targeting IGF-1R and ALK in ALK fusion-positive lung cancer
Christine M. Lovly,Nerina T. McDonald,Heidi Chen,Sandra Ortiz-Cuaran,Lukas C. Heukamp,Yingjun Yan,Alexandra Florin,Luka Ozretić,Diana Lim,Lu Wang,Zhao Chen,Xi Chen,Pengcheng Lu,Paul K. Paik,Ronglai Shen,Hailing Jin,Reinhard Buettner,Sascha Ansén,Sven Perner,Michael Brockmann,Marc Bos,Jürgen Wolf,Masyar Gardizi,Gavin M. Wright,Benjamin Solomon,Prudence A. Russell,Toni Maree Rogers,Yoshiyuki Suehara,Monica Red-Brewer,Rudy Tieu,Elisa de Stanchina,Qingguo Wang,Zhongming Zhao,David H. Johnson,Leora Horn,Kwok-Kin Wong,Roman K. Thomas,Marc Ladanyi,William Pao +38 more
TL;DR: Data support a role for the IGF-1R–IRS-1 pathway in both ALK TKI–sensitive and ALKTKI–resistant states and provide a biological rationale for further clinical development of dual ALK and IGF- 1R inhibitors.
Journal ArticleDOI
CD74-NRG1 fusions in lung adenocarcinoma
Lynnette Fernandez-Cuesta,Dennis Plenker,Hirotaka Osada,Ruping Sun,Roopika Menon,Frauke Leenders,Sandra Ortiz-Cuaran,Martin Peifer,Marc Bos,Juliane Daßler,Florian Malchers,Jakob Schöttle,Jakob Schöttle,Wenzel Vogel,Ilona Dahmen,Mirjam Koker,Roland T. Ullrich,Roland T. Ullrich,Gavin M. Wright,Prudence A. Russell,Zoe Wainer,Benjamin Solomon,Elisabeth Brambilla,Hélène Nagy-Mignotte,Denis Moro-Sibilot,Christian Brambilla,Sylvie Lantuejoul,Janine Altmüller,Christian Becker,Peter Nürnberg,Johannes M. Heuckmann,Erich Stoelben,Iver Petersen,Joachim H. Clement,Jörg Sänger,Lucia Anna Muscarella,Annamaria la Torre,Vito Michele Fazio,Vito Michele Fazio,Idoya Lahortiga,Timothy Perera,Souichi Ogata,Marc Parade,Dirk Brehmer,Martin Vingron,Lukas C. Heukamp,Reinhard Buettner,Thomas Zander,Jürgen Wolf,Sven Perner,Sascha Ansén,Stefan A. Haas,Yasushi Yatabe,Roman K. Thomas +53 more
TL;DR: CD74-NRG1 gene fusions are activating genomic alterations in invasive mucinous adenocarcinomas and may offer a therapeutic opportunity for a lung tumor subtype with, so far, no effective treatment.
Journal ArticleDOI
Heterogeneous mechanisms of primary and acquired resistance to third-generation EGFR inhibitors
Sandra Ortiz-Cuaran,Matthias Scheffler,Dennis Plenker,llona Dahmen,Andreas H. Scheel,Lynnette Fernandez-Cuesta,Lydia Meder,Christine M. Lovly,Thorsten Persigehl,Sabine Merkelbach-Bruse,Marc Bos,Sebastian Michels,Rieke Fischer,Kerstin Albus,Katharina König,Hans-Ulrich Schildhaus,Jana Fassunke,Michaela Angelika Ihle,Helen Pasternack,Carina Heydt,Christian Becker,Janine Altmüller,Hongbin Ji,Christian Müller,Alexandra Florin,Johannes M. Heuckmann,Peter Nuernberg,Sascha Ansén,Lukas C. Heukamp,Johannes Berg,William Pao,Martin Peifer,Reinhard Buettner,Jürgen Wolf,Roman K. Thomas,Martin L. Sos +35 more
TL;DR: The data suggest that heterogeneous mechanisms of resistance can drive primary and acquired resistance to third-generation EGFR inhibitors and provide a rationale for potential combination strategies.
Journal ArticleDOI
Biological functions of p53 isoforms through evolution: lessons from animal and cellular models
Virginie Marcel,Marie-Laure Dichtel-Danjoy,Charlotte Sagne,Charlotte Sagne,Charlotte Sagne,Hind Hafsi,Dali Ma,Sandra Ortiz-Cuaran,Magali Olivier,Janet Hall,Janet Hall,Bertrand Mollereau,Pierre Hainaut,Jean-Christophe Bourdon +13 more
TL;DR: This review summarizes recent advances in the field of ‘p53 isoforms’, including new data on p63 and p73 isoforms, and the deregulation of p53 isoform expression in human cancers is reviewed.